Association of serum IgG N-glycome and transforming growth factor-β1 with hepatitis B virus e antigen seroconversion during entecavir therapy

Cheng Hsun Ho, Rong Nan Chien, Pin Nan Cheng, Cheng Kun Liu, Chih Sheng Su, I. Chin Wu, Wen Chun Liu, Shu Hui Chen, Ting Tsung Chang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aberrant serum IgG N-glycome has been demonstrated in various autoimmune diseases and viral infections. However, the correlation between serum IgG N-glycome and cytokine is unclear. In addition, the clinical relevance of IgG glycosylation and cytokine changes in the treatment outcome of chronic hepatitis B (CHB) has never been assessed. One hundred and three treatment-naive patients with CHB and 101 healthy controls were enrolled in this retrospective cohort study. Serum samples in patients before and after 48 weeks of entecavir treatment were collected. In-gel trypsinized serum IgG heavy chain was analyzed using liquid chromatography-tandem mass spectrometry. Selected ion chromatograms corresponding to 10 N-glycoforms on asparagine 297 were individually extracted to calculate the percentage of each glycoforms. Serum cytokine profiles were examined using enzyme-linked immunosorbent assay. Forty-eight weeks of entecavir treatment resulted in decreases in galactose-deficient (total G0) IgG and transforming growth factor (TGF)-β1 levels (both P < 0.001) in patients with CHB. The changes in TGF-β1 (ΔTGF-β1) and IgG total G0 (Δtotal G0) levels during treatment were significantly correlated (r = 0.403, P < 0.001). Furthermore, higher levels of Δtotal G0 (P < 0.01) and ΔTGF-β1 (P < 0.001) were found in hepatitis B virus e antigen (HBeAg)-positive patients than in HBeAg-negative patients and were also found in patients with HBeAg seroconversion at week 48. The area under the receiver operating characteristic (ROC) curves for Δtotal G0 and ΔTGF-β1 to discriminate a week-48 HBeAg seroconversion were 0.835 and 0.830, respectively. These results suggested a correlation between serum cytokine and IgG N-glycome and its effect on the outcome of entecavir treatment in patients with CHB.

Original languageEnglish
Pages (from-to)121-128
Number of pages8
JournalAntiviral Research
Volume111
DOIs
Publication statusPublished - 2014 Nov

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Virology

Fingerprint Dive into the research topics of 'Association of serum IgG N-glycome and transforming growth factor-β1 with hepatitis B virus e antigen seroconversion during entecavir therapy'. Together they form a unique fingerprint.

  • Cite this